All In Biotech

Drug Trial Radar · NCT07140016

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors are an approved treatment for people with ALK positive NSCLC. Some people stop responding to treatment with ALK inhibitors over time due to more changes happening in their faulty ALK gene, so there is an unmet medical need. Gilteritinib is an approved treatment for people with acute myeloid leukemia (AML) with the faulty FLT3 gene who haven't responded to previous treatment, or their cancer came back after previous treatment. Gilteritinib also blocks changes in the ALK gene which could help people with ALK-positive NSCLC. A study needs to be done with gilteritinib in people with ALK-positive NSCLC. The main aim of the study is to check the safety of gilteritinib in people with ALK-positive NSCLC and if they tolerate gilteritinib. People in this study will be adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Locally advanced means the cancer has spread to nearby tissue. Metastatic means the cancer has spread to other parts of the body. They have stopped responding to treatment with ALK inhibitors, including alectinib or lorlatinib, over time. The key reasons people cannot take part are if they have symptomatic cancers in the brain or nervous system, their cancer has spread to the thin tissue that covers the brain and spinal cord (leptomengingeal metastasis), have recently had or planning to have major surgery, have certain heart conditions, or have recently had an infection, a stroke or mini-stroke. People in the study will take tablets of gilteritinib once a day in a 28-day cycle. They may be given up to 2 different doses of gilteritinib. People in the study will start on the lower dose but can eventually switch to the higher dose if they tolerate the lower dose and meet the safety checks. Whilst taking gilteritinib, people will have regular scans of their tumors. People will continue taking gilteritinib until their cancer gets worse, they have medical problems from gilteritinib that they can't tolerate, they ask to stop taking gilteritinib, they start other cancer treatment or, sadly pass away. People will visit the clinic about 7 days and then 30 days after they stop taking gilteritinib. They will be asked about any medical problems and will have a safety check. After this, people who stopped taking gilteritinib, but their cancer hadn't become worse, will continue to have regular scans of their tumors. If their cancer does get worse, they will no longer have scans of their tumors. After finishing gilteritinib, people will be phoned every 12 weeks to check on their health. People will be in the study for up to 4 years, depending on how they respond to gilteritinib.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Anaplastic Lymphoma Kinase (ALK) Positive

Interventions

  • gilteritinibDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to 28 Days
  2. Number of participants with Adverse Events (AEs)Time frame: Up to approximately 53 Months
  3. Number of participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 53 Months
  4. Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
  5. Number of participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
  6. Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)Time frame: Up to approximately 53 Months
  7. Number of participants with physical exam abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
  8. Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to approximately 53 Months

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center

    Fullerton, California · Recruiting

  • University of California - Irvine

    Orange, California · Recruiting

  • Vail Health Hospital - Shaw Cancer Center

    Edwards, Colorado · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • OSF Health Care

    Peoria, Illinois · Recruiting

  • University of Michigan Health Systems

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Withdrawn

  • UT Southwestern Medical Center at Dallas

    Dallas, Texas · Recruiting

  • Virginia Cancer Specialists PC

    Fairfax, Virginia · Recruiting

  • Site FR33008

    Saint-Herblain, France · Recruiting

  • Site FR33005

    Toulouse, France · Recruiting

  • Site FR33001

    Villejuif, France · Recruiting

  • Site ES34017

    Barcelona, Spain · Recruiting

  • Site ES34006

    Madrid, Spain · Recruiting

  • Site ES34011

    Madrid, Spain · Recruiting

  • Site ES34008

    Málaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.